Story
Summit Therapeutics Shares Surge on Dual Positive Trial Results for Ivonescimab

Summit Therapeutics (NASDAQ: SMMT) saw its stock surge 8.5% in pre-open trading following a pair of significant positive clinical developments for its lead antibody, ivonescimab, which also prompted favorable analyst actions.
Dual Clinical Trial Success
The rally was driven by two key data releases. First, Summit's partner Akeso announced that the Phase III HARMONi-GI1 study for advanced biliary tract cancer met its primary endpoint. The trial showed that ivonescimab demonstrated a statistically significant improvement in overall survival compared to the current standard of care, durvalumab plus chemotherapy. This marks the first successful Phase III result for the drug outside of lung cancer.
Adding to the positive momentum, Summit published the primary analysis of its HARMONi Phase III trial in *The Lancet Oncology*. The study focused on patients with EGFR-mutated non-small cell lung cancer (NSCLC). Results showed that ivonescimab combined with chemotherapy reduced the risk of disease progression by nearly half when compared to a placebo, with a reported hazard ratio of 0.52.
AdAnalyst Upgrades and Market Impact
Wall Street analysts responded positively to the news. Guggenheim reiterated its "Buy" rating and $38 price target, stating that the biliary tract cancer results add consistency to ivonescimab's profile and build confidence for upcoming lung cancer programs. Separately, Bernstein SocGen upgraded the stock to "Market Perform" from "Underperform" and raised its price target to $11.90 from $9.80, reducing a significant source of institutional bearishness.
The stock's strong performance was company-specific, occurring while the broader market was subdued, with the S&P 500 trading flat. For investors, this convergence of a landmark clinical win in a new tumor type, a high-profile publication, and a shift in analyst sentiment creates a compelling catalyst. Attention will now turn to the next major binary event for the company: a U.S. Food and Drug Administration (FDA) decision expected in November.
Read next
More on Stocks
FTC Orders Walmart, Uber, Delta to Disclose Data on Personalized Pricing
The U.S. Federal Trade Commission is demanding nine major companies, including leading retail, travel, and gig economy firms, to provide information on how they use consumer data for setting individual prices and wages.

Google Launches Gemini 4 Carbon AI Model to Bolster Cybersecurity Capabilities
Alphabet's Google has unveiled Gemini 4 Carbon, its latest AI model specifically designed for advanced cybersecurity tasks like vulnerability detection and secure code generation. The launch escalates competition with rivals OpenAI and Anthropic in the enterprise AI market.

Oracle Shares Surge After Unveiling $225 Billion Revenue Target for 2030
Oracle stock rose sharply after the company presented a long-term financial outlook targeting at least $225 billion in annual revenue by fiscal 2030, driven by its expanding AI infrastructure business.

DOJ Scrutinizes Nvidia's $12.9B Hugging Face Deal Amid Broader Antitrust Probe, Sources Say
The U.S. Department of Justice is reportedly examining Nvidia's planned $12.93 billion acquisition of AI platform Hugging Face as part of a wider, ongoing antitrust investigation into the chipmaker's market conduct.